{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:50:56Z","timestamp":1759366256434,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Pathologie"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.annpat.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T16:58:22Z","timestamp":1534957102000},"page":"338-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effets secondaires digestifs et h\u00e9patiques des inhibiteurs du checkpoint immunitaire (Immune checkpoint inhibitors\u00a0: anti-CTLA-4\u00a0et anti-PD-1\/PD-L1)\u00a0: aspects anatomocliniques"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4587-4273","authenticated-orcid":false,"given":"Barbara","family":"Papouin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Guettier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annpat.2018.07.005_bib0255","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2018.07.005_bib0260","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2\u00a0trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0265","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4\u00a0treatment (CheckMate 037): a randomised, controlled, open-label, phase 3\u00a0trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0270","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrgastro.2018.14","article-title":"Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management","volume":"15","author":"Samaan","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0275","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.annpat.2018.07.005_bib0280","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4\u00a0mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.annpat.2018.07.005_bib0285","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4\u00a0leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.annpat.2018.07.005_bib0290","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Auto-immune dilated cardiomyopathy in PD-1\u00a0receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.annpat.2018.07.005_bib0295","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annpat.2018.07.005_bib0300","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0305","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4\u00a0antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.annpat.2018.07.005_bib0310","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti\u2013Cytotoxic T-Lymphocyte Antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0315","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.seminoncol.2010.09.003","article-title":"Update on immunologic therapy with anti-CTLA-4\u00a0antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management","volume":"37","author":"Kaehler","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0320","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4\u00a0blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2018.07.005_bib0325","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/apt.13281","article-title":"Systematic review: colitis associated with anti-CTLA-4\u00a0therapy","volume":"42","author":"Gupta","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.annpat.2018.07.005_bib0330","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4\u00a0therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.annpat.2018.07.005_bib0335","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1\u00a0antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2018.07.005_bib0340","first-page":"190","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1\u00a0therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.annpat.2018.07.005_bib0345","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2018.07.005_bib0350","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I Study of Single-Agent Anti\u2013Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0355","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.annpat.2018.07.005_bib0360","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1\u00a0blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0365","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of Adverse Events Following Treatment With Anti-Programmed Death-1\u00a0Agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.annpat.2018.07.005_bib0370","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/CMR.0000000000000313","article-title":"Anti-programmed cell death protein 1\u00a0tolerance and efficacy after ipilimumab immunotherapy: observational study of 39\u00a0patients","volume":"27","author":"Amode","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annpat.2018.07.005_bib0375","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0380","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1\u00a0therapy in patients with advanced melanoma and preexisting auto-immune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0385","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Auto-immune Disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0390","first-page":"21","article-title":"Safety and efficacy of anti-programmed death 1\u00a0antibodies in patients with cancer and preexisting auto-immune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.annpat.2018.07.005_bib0395","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer Immunotherapy with Anti-CTLA-4\u00a0Monoclonal Antibodies Induces an Inflammatory Bowel Disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.annpat.2018.07.005_bib0400","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s10620-009-0839-8","article-title":"Refractory colitis following anti-CTLA4\u00a0antibody therapy: analysis of mucosal FOXP3+ T cells","volume":"55","author":"Lord","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.annpat.2018.07.005_bib0405","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety Activity, and Immune Correlates of Anti\u2013PD-1\u00a0Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2018.07.005_bib0410","first-page":"11","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4\u00a0by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma","volume":"10","author":"Berman","year":"2010","journal-title":"Cancer Immun"},{"key":"10.1016\/j.annpat.2018.07.005_bib0415","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0420","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/MCG.0b013e31828f1d51","article-title":"Ipilimumab-induced perforating colitis","volume":"47","author":"Mitchell","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0425","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","article-title":"Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1\u00a0Antibodies","volume":"41","author":"Chen","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0430","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.cgh.2015.12.028","article-title":"Clinical Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis","volume":"14","author":"Verschuren","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0435","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/CMR.0000000000000252","article-title":"Anti-PD1-induced collagenous colitis in a melanoma patient","volume":"26","author":"Baroudjian","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annpat.2018.07.005_bib0440","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4\u00a0blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annpat.2018.07.005_bib0445","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1002\/ibd.22846","article-title":"Lymphocytic colitis secondary to ipilimumab treatment","volume":"19","author":"Garc\u00eda-Varona","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.annpat.2018.07.005_bib0450","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/PAS.0b013e31817150e3","article-title":"Alpha-CTLA-4\u00a0mAb-associated panenteritis: a histologic and immunohistochemical analysis","volume":"32","author":"Oble","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0455","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/ecco-jcc\/jjx081","article-title":"Colon Immune-Related Adverse Events: Anti-CTLA-4\u00a0and Anti-PD-1\u00a0Blockade Induce Distinct Immunopathological Entities","volume":"11","author":"Coutzac","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.annpat.2018.07.005_bib0460","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00281-016-0613-x","article-title":"Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?","volume":"39","author":"Carbonnel","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0465","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2018.07.005_bib0470","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2018.07.005_bib0475","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11\u00a0Cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0480","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","article-title":"Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma","volume":"57","author":"Kleiner","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.annpat.2018.07.005_bib0485","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab associated hepatitis: imaging and clinicopathologic findings","volume":"31","author":"Kim","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.annpat.2018.07.005_bib0490","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with auto-immune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0495","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","article-title":"Fibrin Ring Granulomas in Checkpoint Inhibitor-induced Hepatitis","volume":"41","author":"Everett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2018.07.005_bib0500","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2217\/imt-2016-0057","article-title":"Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma","volume":"8","author":"Simonelli","year":"2016","journal-title":"Immunotherapy"}],"container-title":["Annales de Pathologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649818301111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649818301111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:33:36Z","timestamp":1759332816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0242649818301111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0242649818301111"],"URL":"https:\/\/doi.org\/10.1016\/j.annpat.2018.07.005","relation":{},"ISSN":["0242-6498"],"issn-type":[{"type":"print","value":"0242-6498"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets secondaires digestifs et h\u00e9patiques des inhibiteurs du checkpoint immunitaire (Immune checkpoint inhibitors\u00a0: anti-CTLA-4\u00a0et anti-PD-1\/PD-L1)\u00a0: aspects anatomocliniques","name":"articletitle","label":"Article Title"},{"value":"Annales de Pathologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annpat.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}